Tarsus director exercises 302 RSUs into stock

Tarsus Pharmaceuticals, Inc. (TARS) reported that director Wendy L. Yarno exercised 302 Restricted Stock Units (RSUs) on September 15, 2026, settling them into 302 shares of common stock.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) reported that director Wendy L. Yarno exercised 302 Restricted Stock Units (RSUs) on September 15, 2026, settling them into 302 shares of common stock. The RSU award was granted for service as a non-employee director, and no Rule 10b5-1 trading plan is indicated.

After this exercise, Yarno holds 16,956 shares of common stock directly and 907 RSUs directly. Each RSU represents a contingent right to receive one share of Tarsus common stock, vesting in equal installments through June 15, 2027, subject to continuous board service.

Insider Trade Summary

302 shares exercised/converted

Exercise 2 txns

Insider YARNO WENDY L

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F2, F3	302	$0.00	$0.00
Exercise	Common Stock F1	302	--	--

Holdings After Transaction: Restricted Stock Units — 907 contracts (Direct); Common Stock — 16,956 shares (Direct)

Footnotes (3)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
2. F2. Each RSU represents a contingent right to receive one share of the Company's common stock.
3. F3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Key Figures

RSUs exercised: 302 RSUs Common shares received from RSU settlement: 302 shares Common shares held after transaction: 16,956 shares +2 more

5 metrics

RSUs exercised 302 RSUs Settled into common stock on September 15, 2026

Common shares received from RSU settlement 302 shares Issued upon settlement of vested RSUs on September 15, 2026

Common shares held after transaction 16,956 shares Direct ownership by Wendy L. Yarno following the September 15, 2026 transactions

RSUs held after transaction 907 RSUs Direct RSU holdings reported after the September 15, 2026 exercise

RSU vesting dates 4 installments Vest on September 15, 2026; December 15, 2026; March 15, 2027; June 15, 2027

Key Terms

Restricted Stock Units, contingent right, non-employee director, annual meeting of stockholders, +1 more

5 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share"

non-employee director financial

"RSUs granted in connection with the Reporting Person's service as a non-employee director"

annual meeting of stockholders financial

"RSUs granted in connection with service as a non-employee director as of the Company's 2026 annual meeting of stockholders"

continuous service financial

"The RSUs vest in equal installments ... subject to the non-employee director's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tarsus (TARS) disclose for Wendy L. Yarno?

Tarsus disclosed that director Wendy L. Yarno exercised 302 RSUs on September 15, 2026, which were settled into 302 shares of common stock issued for her service as a non-employee director.

How many Tarsus (TARS) common shares does Wendy L. Yarno own after this Form 4?

After the reported transactions, Wendy L. Yarno directly owns 16,956 shares of Tarsus common stock. These holdings reflect the settlement of 302 RSUs into common shares on September 15, 2026.

How many RSUs does Wendy L. Yarno still hold in Tarsus (TARS)?

Following the exercise, Wendy L. Yarno holds 907 Restricted Stock Units (RSUs) directly. Each RSU represents a contingent right to receive one share of Tarsus common stock, subject to vesting and continued service conditions.

What are the vesting terms of Wendy L. Yarno’s RSUs at Tarsus (TARS)?

The RSUs were granted for service as a non-employee director as of the 2026 annual meeting and vest in equal installments on September 15, 2026; December 15, 2026; March 15, 2027; and June 15, 2027, subject to continuous service.

Were Wendy L. Yarno’s Tarsus (TARS) transactions under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan for the reported transactions; the 10b5-1 checkbox is not affirmed, and the footnotes do not describe any pre-arranged trading plan.

Did Wendy L. Yarno buy or sell Tarsus (TARS) shares on the market in this filing?

No market purchases or sales are reported. The Form 4 shows an exercise of 302 RSUs into 302 common shares, with no separate open-market buy or sell transactions disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:23 PM Accepted by SEC EDGAR 09/17/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YARNO WENDY L

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		302	A	(1)	16,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	09/15/2026		M			302	(3)	(3)	Common Stock	302	$0	907	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Each RSU represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)